Indehaveren af markedsføringstilladelsen blev anmodet om at underbygge indikation og dosering som drøftet under den nyligt stedfundne gensidige anerkendelsesprocedure.
The Marketing Authorisation Holder (MAH) was requested to substantiate the indication and posology as discussed during the recent MRP.